Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 11 | 2025 | 744 | 1.730 |
Why?
|
| Hypoglycemic Agents | 9 | 2023 | 181 | 1.400 |
Why?
|
| Insulin | 5 | 2012 | 255 | 0.860 |
Why?
|
| Sulfonylurea Compounds | 2 | 2019 | 17 | 0.690 |
Why?
|
| Metformin | 2 | 2019 | 74 | 0.630 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 18 | 0.630 |
Why?
|
| Cholesterol | 3 | 2013 | 230 | 0.420 |
Why?
|
| Insulin Resistance | 3 | 2012 | 199 | 0.400 |
Why?
|
| Thiazolidinediones | 2 | 2011 | 49 | 0.400 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 25 | 0.400 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 47 | 0.390 |
Why?
|
| Insurance, Health | 1 | 2013 | 143 | 0.370 |
Why?
|
| Pyrazines | 1 | 2011 | 24 | 0.360 |
Why?
|
| Triazoles | 1 | 2011 | 100 | 0.340 |
Why?
|
| Minority Groups | 2 | 2012 | 663 | 0.330 |
Why?
|
| Poverty | 1 | 2012 | 395 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 471 | 0.280 |
Why?
|
| Middle Aged | 11 | 2025 | 11819 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2023 | 1586 | 0.270 |
Why?
|
| Blood Glucose | 4 | 2020 | 386 | 0.270 |
Why?
|
| Hypoglycemia | 2 | 2025 | 24 | 0.260 |
Why?
|
| Cholesterol, LDL | 2 | 2006 | 73 | 0.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 959 | 0.240 |
Why?
|
| Aged | 7 | 2025 | 7982 | 0.240 |
Why?
|
| Adult | 10 | 2025 | 13458 | 0.230 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 10 | 0.220 |
Why?
|
| Lipids | 1 | 2006 | 256 | 0.220 |
Why?
|
| Atherosclerosis | 1 | 2006 | 164 | 0.220 |
Why?
|
| Double-Blind Method | 5 | 2025 | 305 | 0.210 |
Why?
|
| Phytotherapy | 1 | 2004 | 78 | 0.210 |
Why?
|
| Humans | 18 | 2025 | 42163 | 0.190 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 233 | 0.190 |
Why?
|
| Female | 11 | 2025 | 24018 | 0.190 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 263 | 0.180 |
Why?
|
| Male | 10 | 2025 | 22779 | 0.170 |
Why?
|
| Glycemic Index | 1 | 2020 | 10 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2019 | 61 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 85 | 0.150 |
Why?
|
| Antimalarials | 1 | 2019 | 63 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2020 | 1574 | 0.150 |
Why?
|
| Adolescent | 4 | 2013 | 5950 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 733 | 0.130 |
Why?
|
| Young Adult | 3 | 2013 | 4936 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 532 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 729 | 0.120 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 3077 | 0.110 |
Why?
|
| Testosterone | 2 | 2006 | 211 | 0.100 |
Why?
|
| Glucagon-Like Peptides | 2 | 2023 | 5 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2012 | 152 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 236 | 0.090 |
Why?
|
| Cultural Characteristics | 1 | 2012 | 128 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2013 | 487 | 0.090 |
Why?
|
| Exercise | 1 | 2017 | 674 | 0.090 |
Why?
|
| Los Angeles | 1 | 2012 | 390 | 0.090 |
Why?
|
| Perception | 1 | 2012 | 209 | 0.090 |
Why?
|
| Insulin, Long-Acting | 1 | 2010 | 3 | 0.090 |
Why?
|
| Educational Status | 1 | 2012 | 335 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 11 | 0.090 |
Why?
|
| United States | 3 | 2017 | 5072 | 0.080 |
Why?
|
| Cities | 1 | 2010 | 78 | 0.080 |
Why?
|
| Risk Factors | 2 | 2012 | 3942 | 0.080 |
Why?
|
| Weight Gain | 1 | 2010 | 138 | 0.080 |
Why?
|
| Logistic Models | 1 | 2012 | 1001 | 0.080 |
Why?
|
| Nicotine | 1 | 2012 | 290 | 0.080 |
Why?
|
| Apolipoproteins B | 2 | 2006 | 18 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 916 | 0.070 |
Why?
|
| Cholesterol, HDL | 2 | 2006 | 99 | 0.070 |
Why?
|
| Triglycerides | 2 | 2006 | 146 | 0.070 |
Why?
|
| Circadian Rhythm | 1 | 2010 | 234 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 26 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 49 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 195 | 0.060 |
Why?
|
| Fluorine Compounds | 1 | 2025 | 1 | 0.060 |
Why?
|
| Oxadiazoles | 1 | 2025 | 15 | 0.060 |
Why?
|
| Weight Loss | 1 | 2006 | 138 | 0.060 |
Why?
|
| Smoking | 1 | 2012 | 1019 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2006 | 587 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2025 | 256 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 76 | 0.050 |
Why?
|
| Annexin A2 | 1 | 2004 | 6 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 14 | 0.050 |
Why?
|
| Chromans | 1 | 2004 | 14 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2004 | 52 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2004 | 184 | 0.050 |
Why?
|
| Adipocytes | 1 | 2004 | 58 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2023 | 26 | 0.050 |
Why?
|
| Cytokines | 1 | 2006 | 661 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2025 | 1112 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 5 | 0.050 |
Why?
|
| Body Weight | 1 | 2023 | 428 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 293 | 0.040 |
Why?
|
| Fructosamine | 1 | 2020 | 2 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2020 | 58 | 0.040 |
Why?
|
| Quality of Life | 1 | 2004 | 599 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2006 | 2485 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 97 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 850 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1051 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 2012 | 16 | 0.020 |
Why?
|
| Hypogonadism | 1 | 2012 | 23 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 2012 | 60 | 0.020 |
Why?
|
| HIV Infections | 1 | 2006 | 2535 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2006 | 14 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2006 | 37 | 0.020 |
Why?
|
| Thrombosis | 1 | 2006 | 81 | 0.010 |
Why?
|
| California | 1 | 2006 | 531 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2004 | 61 | 0.010 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2004 | 14 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 79 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 725 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 708 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 230 | 0.010 |
Why?
|
| Biological Transport | 1 | 2004 | 201 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 254 | 0.010 |
Why?
|
| Glucose | 1 | 2004 | 242 | 0.010 |
Why?
|
| Apolipoproteins C | 1 | 2002 | 3 | 0.010 |
Why?
|
| Apolipoprotein C-III | 1 | 2002 | 7 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 16695 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 115 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 164 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 729 | 0.010 |
Why?
|
| Estradiol | 1 | 2002 | 269 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 6490 | 0.010 |
Why?
|